Summary Human cancers frequently sustain genetic mutations that alter the function of their G1 cell cycle control check point. These include changes to the retinoblastoma gene and to the genes that regulate its phosphorylation, such as the cyclin-dependent kinase inhibitor p16
Many human cancers harbour genetic changes that alter the function of the G1 cell cycle control check point (reviewed in Sherr and Roberts, 1995; Hall and Peters, 1996; Palmero and Peters, 1996; Herwig and Strauss, 1997) . The common outcome of these changes is the functional deregulation of the retinoblastoma protein (pRb). pRb directly interacts with and regulates the activity of a series of RNA polymerase I, II and III dependent transcription factors including members of the E2F family, MyoD and Elf-1 Sanchez and Dynlacht, 1996; Herwig and Strauss, 1997) . The activity of pRb is regulated in turn by its phosphorylation status (Weinberg, 1995; Herwig and Strauss, 1997; Mittnacht, 1998) . In non-proliferating or quiescent cells, pRb is hypophosphorylated and active. However, in response to appropriate growth conditions, cells enter into the G1 phase of the cell division cycle, and cyclin-dependent kinase 4 (cdk4) and cdk6, in conjunction with members of the cyclin D family, and cdk2, in conjunction with cyclin E, phosphorylate pRb protein resulting in its inactivation. This releases both the pRb-associated transcription factors and the cell cycle control check point and allows cells to progress from G1 into S phase (Weinberg, 1995; Herwig and Strauss, 1997; Mittnacht, 1998) . Members of the p16
INK4a and p21 CIP1 cdk-inhibitor families also influence the activity of pRb by directly inhibiting phosphorylation of pRb protein by the cdks Herwig and Strauss, 1997; Mittnacht, 1998) . Thus, information from both positive and negative extracellular signals is integrated into a simple 'stop' or 'go' message at the G1 checkpoint by influencing the ability of the cyclin D-cdk and cyclin E-cdk complexes to phosphorylate pRb protein.
The retinoblastoma gene itself is a target for genetic alterations in many types of cancer (reviewed in Palmero and Peters, 1996) . The resulting deletions and point mutations either destroy the coding capacity or else encode for non-functional versions of pRb protein (Cowell and Hogg, 1992; Weinberg, 1992) . In cells that have sustained homozygous mutations to the retinoblastoma gene, pRb is constitutively inactive and, as a consequence, the pRbdependent cell cycle check point cannot be imposed. Thus, mutation of the retinoblastoma gene can contribute to the deregulated proliferation of cancer cells.
The retinoblastoma gene is expressed in a cell cycle-dependent manner in normal human B-cells. As quiescent (Go) cells enter into the cell division cycle in response to relevant extracellular signals, two changes to pRb protein become apparent: the overall level of expression increases and the protein becomes phosphorylated on multiple sites (Sinclair et al, 1994 (Sinclair et al, , 1998 Hollyoake et al, 1995; Kempkes et al, 1995; Szekely et al, 1995; Cannell et al 1996) . Altered expression of pRb has been described in primary samples derived from high grade non-Hodgkin's lymphoma (NHL) (Martinez et al, 1993) and expression is lost in 58% of centroblastic and Burkitt's lymphomas (Weide et al, 1994) .
Cell lines derived from Burkitt's lymphomas and from Epstein-Barr virus (EBV) transformed human B-cells are frequently used as in vitro model systems to ask questions about the effects of extracellular signalling on the proliferation of B-cells (for example, Sinclair et al, 1993; Holder et al, 1993; Allday et al, 1995; Arvanitakis et al, 1995; MacDonald et al, 1996) . Since pRb is involved in integrating a wide range of signal transduction pathways, it is important to determine whether or not established human B-cell lines express functional pRb protein.
In this report, the expression and the functional status of the retinoblastoma gene in 11 human B-cell lines are examined.
MATERIALS AND METHODS

Cell culture
The human B-lymphoid cell lines were maintained in RPMI supplemented with 15% (v/v) fetal calf serum, penicillin and streptomycin at between 2 and 8 × 10 5 cells per ml to ensure that they were in exponential growth. Ramos , DG75 (Ben-Bassat et al, 1977) , Akata (Takada, 1984) , Rael (Klein et al, 1972) , Mutu Cl 179 (Gregory et al, 1990) , Mutu Cl 148 (Gregory et al, 1990) and Jijoye (Hinuma et al, 1967) were originally derived from Burkitt's lymphomas. LCL#3 (Sinclair et al, 1994) , B95-8PF (Farrell et al, 1991) and IB4 (King et al, 1980) were established by immortalization of primary B-cells with the B95-8 strain of EBV. BJAB was originally derived from an EBV-negative B-lymphoma and does not harbour any of the c-myc/immunoglobulin translocations that are characteristic of Burkitt's lymphoma (Clements et al, 1975; Menezes et al, 1975) . SAOS (Diller et al, 1990 ) and U2OS (Ponten and Saksela, 1967) were originally derived from osteosarcomas.
Quiescent primary B-cells were isolated from donated human blood using affinity purification with anti-CD19 coated magnetic beads (Dynal) as described previously (Sinclair et al, 1994; Sinclair and Farrell, 1995) .
Protein analysis
Total protein extracts were prepared from exponentially growing cell lines and from quiescent primary B-cells as described previously (Cannell et al, 1996) . The protein concentrations were normalized after comparing the absorption at 280 nm. A total of 100 µg of each extract was fractionated on a sodium dodecyl sulphate (SDS)-polyacrylamide gel, transferred to polyvinylidene difluoride (PVDF) membrane (Immobilon-P) and processed as described previously (Cannell et al, 1996) .
For the analysis of pRb protein, extracts were fractionated in a 10% gel and a monoclonal antibody used to detect the protein (14001A; Pharmingen). For the analysis of p16
INK4a protein, extracts were fractionated in a 15% gel and a monoclonal antibody was used to detect the protein (DCS50; Lukas et al, 1995a) . For the analysis of p15
INK4b protein, extracts were fractionated in a 15% gel and a rabbit polyclonal antisera was used to detect the protein (K-18; Santa Cruz). For cdk4, proteins were fractionated in a 12.5% gel and a rabbit polyclonal antiserum was used to detect the protein (Bates et al, 1994) . In each case an HRP-conjugated species-specific secondary antibody step was included and the signals were detected by enhanced chemiluminescence (ECL) after exposure to autoradiography (Amersham).
Complex formation
Extracts were prepared by lysing cells in NP40 lysis buffer (50 mM Hepes pH 8.0; 1% (v/v) NP-40; 0.1% (v/v) Tween-20; 150 mM sodium chloride; 1 mM EDTA; 2.5 mM EGTA; 1 mM NaF; 10% (v/v) glycerol, 1 mM dithiothreitol; 'complete protease inhibitor' (Boehringer Mannheim)). Debris was removed from the extract by centrifugation (1000 rpm for 10 min in a Beckman J6B centrifuge). The extract was precleared by incubation with a mixture of protein A and protein G Sepharose for 45 min rocking at 4°C. Sepharose beads were removed by centrifugation (1000 rpm for 10 min in a Beckman J6B centrifuge). Cyclin D3 and any associated proteins were isolated from the precleared extract by precipitation with a cyclin D3 monoclonal antibody (DCS28; Welcker et al, 1996; Bartokova et al, 1998) . For the IB4 extract only, a combination of DCS28 and a cyclin D2-specific antibody, DCS5.2 (Lukas et al, 1995b ) was used to isolate both cyclin D2 and cyclin D3 associated proteins. A mock precipitation with control mouse antibodies (Sigma) was undertaken in parallel. The precipitated complexes were collected on a combination of Protein A and Protein G Sepharose beads (Sigma) and washed extensively with lysis buffer and then once with 50 mM Tris-HCl, pH 7.5. The proteins were then eluted from the beads by heating at 95°C for 5 min in 2 ϫ PS buffer (0.12 M Tris pH 6.8; 4% (v/v) SDS; 20% (w/v) glycerol; 2% (v/v) β-mercaptoethanol; 0.01% (w/v) bromophenol blue) and fractionated on a 12.5% SDS-polycrylamide gel. Cdk4 protein in the complexes was detected by Western blot analysis using the rabbit polyclonal antiserum described above (Bates et al, 1994 ).
Densitometric analysis
The relative level of p16
INK4a protein detected by Western blot analysis was quantitated by densitometric analysis using Image Quant (Pharmacia) software.
RESULTS
pRb protein is expressed and regulated by phosphorylation in human B-lymphoid cell lines
The expression of pRb protein was surveyed in a series of wellcharacterized cell lines originally derived from Burkitt's lymphomas; Ramos, DG75, Akata, Rael, Mutu Cl 179, Mutu Cl 148 and Jijoye (Figure 1) , and a B-cell lymphoma, BJAB (data not shown). In addition, three lymphoblastoid cell lines that had been previously immortalized with EBV in vitro; LCL#3 and B95-8PF ( Figure 1 ) and IB4 (data not shown), were included in the analysis. The osteosarcoma cell lines, SAOS and U2OS, were analysed in parallel as controls. The SAOS cell line is known not to express detectable pRb protein, whereas the U2OS cell line expresses similar levels of pRb protein as proliferating primary human cells (Koh et al, 1995; Lukas et al, 1995a) (Figure 1) . A single band of low intensity was observed in the sample of normal primary B-cells (PB). These cells were isolated from the peripheral circulation and the majority of the population were quiescent naive B-cells (Sinclair et al, 1994; Sinclair and Farrell, 1995) . The single pRb band corresponded to the hypophosphorylated form of pRb which is characteristic of this cell type (Cannell et al, 1996) . In contrast, all of the B-cell lines and the U2OS cell line displayed stronger signals with the pRb antibody. These appeared as a broad ladder or smear of bands, which corresponded to the multiply phosphorylated forms of pRb that are characteristic of proliferating cells (Buchkovich et al, 1989; Ludlow et al, 1989; Xu et al, 1989) . Thus, all 11 of the B-lymphoid cell lines contained equivalent levels of pRb protein, which is present in the hyperphosphorylated forms expected for proliferating cells.
Analysis of pRb function in B-lymphoid cell lines
Although non-functional mutant forms of pRb do not generally exist in hyperphosphorylated forms (Scheffner et al, 1991; Templeton et al, 1991) , the analysis of protein expression by Western blotting was not able to distinguish unequivocally between functional proteins and those that had sustained either small deletions within the coding sequence or point mutations which rendered them non-functional. We therefore sought further evidence to define whether the pRb proteins observed in this panel of B-cell lines were functional.
One consequence of the loss of pRb function in human cell lines is the increased expression of the cdkI gene p16
INK4a (Serrano et al, 1993; Li et al, 1994; Otterson et al, 1994; Tam et al, 1994; Aagaard et al, 1995; He et al, 1995; Kelley et al, 1995; Kratzke et al, 1995; Lukas et al, 1995a; Musgrove et al, 1995; Parry et al, 1995; Shapiro et al, 1995a,b; Bartkova et al, 1996; Hara et al, 1996; Khleif et al, 1996; Itoh et al, 1997; Ruas and Peters, 1998) . As illustrated in Figure 2, INK4a protein in the cell and allowing cdk4 and cdk6 to form active complexes with cyclin D and so phosphorylate pRb. As illustrated in Figure 2B , it is apparent that the functional inactivation of pRb disrupted this regulation, resulting in increased transcription of p16
INK4a and the accumulation of high levels of p16
INK4a protein within a cell. Indeed, it has been observed that human cell lines lacking functional pRb contain so much p16
INK4a protein that no cyclin D-cdk4 or cyclin D-cdk6 complexes are formed (for example Serrano et al, 1993; Tam et al, 1994; Aagaard et al, 1995; Parry et al, 1995) .
Thus, in a situation where apparently full-length pRb is expressed and the p16
INK4a locus has not been deleted or silenced by methylation, the functional status of pRb can be questioned In order to question whether pRb is functional in the panel of Bcell lines, the level of expression of p16
INK4a protein was compared between the B-cell lines and the control cell lines. All of the samples were fractionated on the same gel and analysed in an identical fashion. As had been shown previously, the U2OS cell line did not express p16
INK4a protein whereas the SAOS cell line, which did not express any pRb protein (Figure 1) , contained characteristically high levels of p16
INK4a protein (Lukas et al, 1995a ) ( Figure  3A ). These two lines were included in the analysis as positive and negative controls. In comparison to the signal observed in SAOS cells, the normal B-cells (PB) and the B-lymphoid cell lines expressed p16
INK4a protein at levels that were just detectable in this assay ( Figure 3A) . The expression of the related cdkI p15
INK4a
, which is not regulated by pRb, was also compared between this panel of cell lines. p15
INK4b did not show the same marked variation in expression ( Figure 3B ).
When the level of p16 INK4a protein in the cell lines was quantitated, it became clear that there was some variation in the levels of INK4a protein between the B-cell lines ( Figure 3C ). However, the striking feature of the analysis was that none of the Blymphoid cell lines expressed p16
INK4a proteins at significantly higher levels than the normal primary B-cells, and none at levels comparable to that observed in the SAOS cell line. Thus, the level of p16
INK4a protein within these B-lymphoid cell lines was consistent with the retention of functional pRb.
As a further test of the functional status of pRb within these cells, we analysed whether cyclin D-cdk4 complexes could be formed in four representative cell lines: an LCL (IB4), an EBVpositive Burkitt's lymphoma (Rael) and two EBV-negative Burkitt's lymphoma cell lines (DG75 and Ramos). These cell lines displayed characteristic differences in their expression of members of the cyclin D family; LCLs expressed predominantly cyclin D2, whereas the other cell lines expressed only cyclin D3 (Palmero et al, 1993; Pokrovskaja et al, 1996; Bartekova et al, 1998) . In all four cell lines, isolation of complexes containing the relevant cyclin D protein resulted in the co-purification of cdk4 (Figure 4) . Thus, the p16
INK4a protein in these cell lines remained below the threshold required to disrupt cyclin D-cdk4 complexes, which further strengthened our general conclusion that pRb is functional in this panel of human B-lymphoid-derived cell lines.
DISCUSSION
Although the incidence of genetic alteration to the retinoblastoma gene is high in non-Hodgkin's lymphomas (NHL) (Martinez et al, 1993; Weide et al, 1994) , we have identified 11 human B-cell lines which express pRb protein. This suggests that at least one allele of the retinoblastoma gene is intact in the cell lines. Furthermore, since (i) the pRb/p16
INK4a feedback loop does not appear to have been disrupted and (ii) cyclin D-cdk4 complexes exist in the cells, this suggests that the pRb protein is functional and so inactivating point mutations are unlikely to have occurred. These cell lines may therefore prove to be a useful background in which to investigate the consequences of experimentally disrupting pRb function in human B-cells.
It is intriguing that the published incidence of pRb lesions is higher in B-lymphoid malignancies than B-lymphoid cell lines. However, the discovery that the loss of functional pRb can promote apoptosis (Morganbesser et al, 1994; Pan and Griep, 1994) may suggest an explanation for this difference. Thus, a model can be formulated whereby B-cell tumours lacking functional pRb exist in vivo due to the presence of survival factors expressed by neighbouring cells; however, once they are removed from their microenvironment and placed into in vitro culture, they will not survive. Thus, it is likely that established B-lymphoid cell lines represent only a subset of the tumours.
The presence of slower migrating bands of pRb, as seen in Figure 1 , shows that the pRb phosphorylation pathway is active in these cells. However, since components of this pathway are frequently subject to mutation in lymphoid malignancies it is worth considering whether other components of the pathway are likely to be compromised in these cell lines.
i. A chromosomal translocation, t(11;14) (Banks et al, 1992; Shivdasani et al, 1993; Harris et al, 1994) , which juxtaposes the cyclin D1 gene with an immunoglobulin enhancer and thus drives the unscheduled expression of cyclin D1 in B-cells (reviewed in Hall and Peters, 1996) , is associated with a subset of B-lymphomas (Mantle cell lymphomas). However, this translocation has not been found in Burkitt's lymphomas, which is consistent with the fact that no cyclin D1 protein or mRNA has been detected in an extensive group of cell lines derived from Burkitt's lymphomas or EBV immortalized Bcells (Palmero et al, 1993; Pokrovskaja et al, 1996) . ii. Homozygous deletion of the MTS1 (CDKN2A, p16
INK4a
) locus is detected in a wide range of lymphoid malignancies (reviewed in Ruas and Peters, 1998) . This results in a lack of expression of p16
INK4a protein. As shown in Figure 3A , we were able to detect p16
INK4a protein of the expected molecular weight in all of the B-cell lines, which implies that the locus has not been lost from this panel of cell lines. iii. Point mutations within the p16
INK4a coding sequence have also been observed in non-lymphoid malignancies (reviewed in Ruas and Peters, 1998) . Although some of these changes are silent, some result in the expression of a protein which has lost its ability to inhibit cdk4 and cdk6. Although such point mutations are extremely rare in lymphoid malignancies (Ruas and Peters, 1998), we have not eliminated the possibility that they may be present in some of these B-cell lines. iv. In addition, the molecular mechanisms by which p16 INK4a expression can be altered includes silencing of the locus by site-specific methylation Merlo et al, 1995; Otterson et al, 1995; Shapiro et al, 1995a,b) . However, since we were able to detect expression of p16
INK4a protein in these B-cell lines, this silencing mechanism is unlikely to play a significant role here.
The possibility remains that the p16 INK4a /pRb pathway is disrupted further downstream or bypassed in these cells. For example, it has been shown recently that elevated expression of either cyclin E or c-myc is able to promote G1 to S phase transition in the presence of hypophosphorylated, active pRb (Alevizopoulos et al, 1997; Leone et al, 1997; Lukas et al, 1997) . Since all Burkitt's lymphoma cells express elevated levels of c-myc due to a translocation involving c-myc and one of the immunoglobulin loci (Rickinson and Keiff, 1996) , this may reduce the selective pressure for mutations in the p16 INK4a /pRb pathway during the development of the tumour.
Thus, this panel of 11 cell lines, derived originally from B-cell malignancies (Burkitt's lymphomas) or Epstein-Barr virus transformation (lymphoblastoid cell lines) appear to express functional pRb and contain an active pRb phosphorylation pathway. In addition, this analysis demonstrates that the MTS1 locus is not silenced in the cell lines. From this, it can be concluded that neither the Cell Line DG75 Rael Ramos IB4
IP antibody -C D3 -C D3 -C D3 -C D2 -CDK4 Figure 4 Formation of cyclin D-cdk4 complexes in DG75 cells. NP-40 extracts were prepared from the indicated cell lines. After incubation with either anti-cyclin D3 alone (D3) or a combination of anti-cyclin D3 and anticyclin D2 primary antibodies (D2), or a control mouse IgG (C), or no antibody (-) the resulting complexes were isolated on a combination of protein A and protein G Sepharose beads and fractionated on a 12.5% SDS-acrylamide gel. The presence of cdk4 protein in the complexes was determined by Western blot analysis disruption of pRb function nor the silencing of MTS1 are absolutely required either for the generation of B-cell malignancies or for the subsequent outgrowth of B-cell lines.
